A high HRD score has been shown to be predictive of clinical benefit with PARP inhibitor therapy, independent of BRCA1/2 status in ovarian cancer, but its predictive value of sensitivity to PARP inhibitors or platinum in other tumor types is still unclear16–20. The gene discussed is BRCA1; the disease is neoplasm.